Navigation Links
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management

SAN DIEGO, July 31, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new generation monitoring test, PROMETHEUS Anser IFX.  This test measures drug (infliximab) and drug antibody levels in one sample among inflammatory bowel disease (IBD) patients using infliximab – helping physicians identify potential causes for loss of treatment response and helping to guide patient management decisions. This is the first commercial test utilizing Prometheus' proprietary homogenous mobility shift assay (HMSA) platform technology. Prometheus intends to use this platform for subsequent introductions of additional tests targeted to other biologic agents being used to treat a variety of autoimmune diseases.

The Crohn's and Colitis Foundation of America estimates that approximately 1.4 million Americans suffer from IBD.  Approximately 50% of IBD patients using infliximab may eventually experience a loss of treatment response during their treatment.  For some patients, this loss of treatment response may be the result of insufficient infliximab levels.  For others, the loss may be due to the development of antibodies to infliximab (ATI).  If the loss of treatment response is due to the development of ATI, increasing the infliximab dose – the most common first step for physicians – may be less effective than switching to another treatment agent. PROMETHEUS Anser IFX test was verified with more than 3,000 IBD clinical patient samples.

"The need for PROMETHEUS Anser IFX is high, and its availability marks the latest milestone in our continuing commitment to significant advancements in personalized medicine for gastroenterologists, patients and healthcare providers," said Joseph M. Limber, President and Chief Executive Officer of Prometheus.  "PROMETHEUS Anser IFX provides significant value to the IBD patient using infliximab and his or her treating physician – potentially saving time and effort in guiding treatment decisions when response to infliximab is lost."

About IBD
IBD, including Crohn's disease and ulcerative colitis, is a chronic inflammatory condition of the intestinal tract. Symptoms of the disease may include diarrhea, abdominal pain, fever and rectal bleeding. Patients may require long-term medical care, including hospitalizations, surgeries and therapeutics. The condition can be difficult to diagnose and manage clinically while consuming a substantial amount of healthcare resources in terms of physician time, procedures and medications.

About Infliximab
Infliximab belongs to a class of drugs called tumor necrosis factor (TNF) blockers. TNF blockers suppress the immune system by blocking the activity of TNF, a substance in the body that can cause inflammation and lead to autoimmune diseases. In addition to being approved for ulcerative colitis, infliximab is approved for the treatment of other autoimmune diseases such as Crohn's disease in adults and children 6 years and older, as well as rheumatoid arthritis, ankylosing spondylitis (arthritis affecting the joints in the spine and the pelvis), psoriatic arthritis (joint pain associated with psoriasis), and plaque psoriasis in adults. The drugs in this class include Remicade® (infliximab), Enbrel® (etanercept), Humira® (adalimumab), Cimzia® (certolizumab pegol) and Simponi® (golimumab).

About Prometheus
Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with more targeted solutions to optimize care for their patients. Prometheus became part of Nestlé Health Science in July 2011.  Prometheus' corporate offices are located in San Diego, California. For more information about Prometheus, please visit

About Nestle Health Science
Nestle Health Science, a fully-owned subsidiary of Nestle S.A., has been operational since January 1, 2011 and has worldwide headquarters in Lutry, Switzerland. Nestle Health Science offers nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages. For more information about Nestle Health Science, please visit

REMICADE is a registered trademark of Centocor Ortho Biotech Inc.
HUMIRA is a registered trademark of Abbott Laboratories.
CIMZIA is a registered trademark of the UCB group of companies.
ENBREL is a registered trademark of Immunex Corporation
SIMPONI is a registered trademark of Johnson & Johnson

SOURCE Prometheus Laboratories Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
2. Women Health Expert GC-Rise Launches Obstetrician-gynecologist Prize
3. Elsevier Launches New Open Access Journal: Applied and Translational Genomics
4. The Gomez Law Firm Launches New Website Representing Victims Of Defective Stryker Hip Replacement Systems
5. AHIMA Launches First HIM Career Map
6. BD Launches New Needle Designed to Improve Performance and Patient Comfort
7. Avion Pharmaceuticals, LLC., Launches Prenate Mini
8. Codman Neurovascular Launches Two New Microcoil Systems, New Distal Access Catheter At SNIS
9. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies
10. Sanofi US Launches Collaborate Activate Innovation Challenge
11. Berg Pharma launches clinical trial on BPM 31543 for prevention of chemotherapy-induced alopecia (CIA)
Post Your Comments:
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... Research and Markets ( ) has announced the ... report to their offering. ... author the present scenario and growth prospects of the ... market size, the report considers revenue generated from the ... copper IUDs. The report forecasts the global intrauterine devices ...
(Date:11/26/2015)... November 26, 2015 Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Research . --> Clinical Cancer Research . ...
Breaking Medicine Technology:
(Date:11/26/2015)... Toronto, ON and Cambridge, ON (PRWEB) , ... ... ... announced today the availability of a real-time eReferral system for diagnostic imaging in ... CTs, ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating ... our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an accomplishment ... day excited to rebuild lives and it’s an honor to have served all of ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center ... reliability. , The new Q-Suite 6 platform is based on the latest Java Enterprise ... a specific piece of software for many key components of the suite. Much of ...
Breaking Medicine News(10 mins):